GT Biopharma Announces First Patient Dosed in Phase 1 Trial of GTB-5550, a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid Tumors

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. ACN
3. NVDA
4. APGE
5. USO
6. GOOGL
7. MU
8. HOOD
9. DFTX
10. RGNX

Go back to GT Biopharma Announces First Patient Dosed in Phase 1 Trial of GTB-5550, a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid Tumors
(NASDAQ: GTBP) Delayed: 0.50 -0.01 (1.96%)
Previous Close $0.51    52 Week High $ 
Open $0.54    52 Week Low $ 
Day High $0.56    P/E N/A 
Day Low $0.50    EPS $ 
Volume 2,643,179